alopecia

Posts

Alopecia Treatment Market

Alopecia Treatment Market

/in /by

Global Alopecia Treatment (Hair Loss) Market– Industry Trends and Forecast to 2026

The Global Alopecia Treatment (Hair Loss) Market is expected to rise from its initial estimated value of USD 8.21 billion in 2018 to an estimated value of USD 12.40 billion by 2026 registering a CAGR of 5.3% in the forecast period of 2019-2026. This rise in the market can be attributed to the rising geriatric population along with high demand for surgical hair transplant and changing lifestyle.

Market Definition: Global Alopecia Treatment (Hair Loss) Market

Alopecia areata is a medical condition which is a type of alopecia which attacks the hair follicles causes the breakage or fall of hair leading to complete baldness. The patient suffering from alopecia areata, their scalp becomes patchy, diffused and confluent pattern leading the hair fall initially and later spread over the entire scalp termed as alopecia totalis or entire epidermis.

Alopecia areata is an autoimmune hair loss on the scalp or on the body and commonly it shows a form of solitary and multiple patches of alopecia.

Market Drivers:

  • The rising geriatric population along with high demand for surgical hair transplant will boost the market
  • Changing lifestyle along with increase in stress level among working-class population can fuel the growth of the market

Market Restraints:

  • High cost of alopecia treatment (hair loss) is acting as a major restraint for the market
  • Side effects/allergic reactions by treatment also acting as a major market restraint.

Segmentation: Global Alopecia Treatment (Hair Loss) Market

  • By Disease Type
    • Androgenic Alopecia
    • Alopecia Areata
    • Ciatricial Alopecia
    • Traction Alopecia
    • Alopecia Totalis
  • By Drug Type
    • Minoxidil
    • Finasteride
    • Cyclosporine
    • Others
  • By Gender
    • Male
    • Female
  • By Route of Administration
  • Oral
    • Topical
    • Injectable
  • By Distribution Channel
    • Hospital
    • Retail Pharmacies
    • Online Pharmacies
  • By Geography
    • North America
      • US
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Rest of South America
    • Europe
      • Germany
      • France
      • United Kingdom
      • Italy
      • Spain
      • Russia
      • Turkey
      • Belgium
      • Netherlands
      • Switzerland
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • South Korea
      • India
      • Australia
      • Singapore
      • Malaysia
      • Indonesia
      • Thailand
      • Philippines
      • Rest of Asia-Pacific
    • Middle East and Africa
      • South Africa
      • Egypt
      • Saudi Arabia
      • United Arab Emirates
      • Israel
      • Rest of Middle East and Africa

Key Developments in the Market:

  • In January 2018, Concert Pharmaceuticals, Inc. announced U.S. FDA granted Fast Track designation for CTP-543, a novel, oral Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe alopecia areata, a disease which attacks the hair follicles, leading to hair loss.
  • In May 2018, Histogen, Inc (U.S.) announced that received approval to Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) to study its lead product in female diffuse hair loss.
  • In March 2017, Perrigo Perrigo Company PLC (U.S.) announced the launch of over-the-counter Women’s Rogaine, which helps to regrow hair on top of the scalp.

Competitive Analysis: Global Alopecia Treatment (Hair Loss) Market

The global alopecia treatment (hair loss) market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of alopecia treatment (hair loss) market for global, Europe, North America, Asia Pacific, South America and Middle East & Africa.

Key Market Competitors: Global Alopecia Treatment (Hair Loss) Market

Few of the major market competitors currently working in the alopecia treatment (hair loss) market are Cipla, Viviscal, Dr. Reddy’s Laboratories Ltd., Regaine, Merck & Co., Inc, Ranbaxy Laboratories Ltd, Phyto – Alès Groupe, Kirkland Signature, Vitabiotics, Nanogen, Alpecin – Dr. Kurt Wolff GmbH & Co. KG, Rogaine – Johnson and Johnson, Histogen, Inc., Aclaris Therapeutics, Inc., Concert Pharmaceuticals, Inc., HCell Inc., GlaxoSmithKline plc., Perrigo Company PLC. and Daiichi Sankyo, Inc.

Research Methodology: Global Alopecia Treatment (Hair Loss) Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report.

The key research methodology used by DBMR Research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents:

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report:

  • Current and future of global alopecia treatment (hair loss) market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

  • All segmentation provided above in this report is represented at country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Global Alopecia Treatment (Hair Loss) Market– Industry Trends and Forecast to 2026

Source

Recent Posts

Alopecia Treatment Market

Alopecia Treatment Market

/in /by

Global Alopecia Treatment (Hair Loss) Market– Industry Trends and Forecast to 2026

The Global Alopecia Treatment (Hair Loss) Market is expected to rise from its initial estimated value of USD 8.21 billion in 2018 to an estimated value of USD 12.40 billion by 2026 registering a CAGR of 5.3% in the forecast period of 2019-2026. This rise in the market can be attributed to the rising geriatric population along with high demand for surgical hair transplant and changing lifestyle.

Market Definition: Global Alopecia Treatment (Hair Loss) Market

Alopecia areata is a medical condition which is a type of alopecia which attacks the hair follicles causes the breakage or fall of hair leading to complete baldness. The patient suffering from alopecia areata, their scalp becomes patchy, diffused and confluent pattern leading the hair fall initially and later spread over the entire scalp termed as alopecia totalis or entire epidermis.

Alopecia areata is an autoimmune hair loss on the scalp or on the body and commonly it shows a form of solitary and multiple patches of alopecia.

Market Drivers:

  • The rising geriatric population along with high demand for surgical hair transplant will boost the market
  • Changing lifestyle along with increase in stress level among working-class population can fuel the growth of the market

Market Restraints:

  • High cost of alopecia treatment (hair loss) is acting as a major restraint for the market
  • Side effects/allergic reactions by treatment also acting as a major market restraint.

Segmentation: Global Alopecia Treatment (Hair Loss) Market

  • By Disease Type
    • Androgenic Alopecia
    • Alopecia Areata
    • Ciatricial Alopecia
    • Traction Alopecia
    • Alopecia Totalis
  • By Drug Type
    • Minoxidil
    • Finasteride
    • Cyclosporine
    • Others
  • By Gender
    • Male
    • Female
  • By Route of Administration
  • Oral
    • Topical
    • Injectable
  • By Distribution Channel
    • Hospital
    • Retail Pharmacies
    • Online Pharmacies
  • By Geography
    • North America
      • US
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Rest of South America
    • Europe
      • Germany
      • France
      • United Kingdom
      • Italy
      • Spain
      • Russia
      • Turkey
      • Belgium
      • Netherlands
      • Switzerland
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • South Korea
      • India
      • Australia
      • Singapore
      • Malaysia
      • Indonesia
      • Thailand
      • Philippines
      • Rest of Asia-Pacific
    • Middle East and Africa
      • South Africa
      • Egypt
      • Saudi Arabia
      • United Arab Emirates
      • Israel
      • Rest of Middle East and Africa

Key Developments in the Market:

  • In January 2018, Concert Pharmaceuticals, Inc. announced U.S. FDA granted Fast Track designation for CTP-543, a novel, oral Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe alopecia areata, a disease which attacks the hair follicles, leading to hair loss.
  • In May 2018, Histogen, Inc (U.S.) announced that received approval to Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) to study its lead product in female diffuse hair loss.
  • In March 2017, Perrigo Perrigo Company PLC (U.S.) announced the launch of over-the-counter Women’s Rogaine, which helps to regrow hair on top of the scalp.

Competitive Analysis: Global Alopecia Treatment (Hair Loss) Market

The global alopecia treatment (hair loss) market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of alopecia treatment (hair loss) market for global, Europe, North America, Asia Pacific, South America and Middle East & Africa.

Key Market Competitors: Global Alopecia Treatment (Hair Loss) Market

Few of the major market competitors currently working in the alopecia treatment (hair loss) market are Cipla, Viviscal, Dr. Reddy’s Laboratories Ltd., Regaine, Merck & Co., Inc, Ranbaxy Laboratories Ltd, Phyto – Alès Groupe, Kirkland Signature, Vitabiotics, Nanogen, Alpecin – Dr. Kurt Wolff GmbH & Co. KG, Rogaine – Johnson and Johnson, Histogen, Inc., Aclaris Therapeutics, Inc., Concert Pharmaceuticals, Inc., HCell Inc., GlaxoSmithKline plc., Perrigo Company PLC. and Daiichi Sankyo, Inc.

Research Methodology: Global Alopecia Treatment (Hair Loss) Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report.

The key research methodology used by DBMR Research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents:

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report:

  • Current and future of global alopecia treatment (hair loss) market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

  • All segmentation provided above in this report is represented at country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Global Alopecia Treatment (Hair Loss) Market– Industry Trends and Forecast to 2026

Source

Recent Posts

Alopecia Treatment Market

Trial for Androgenic Alopecia

/in /by

Histogen Announces Completion of Patient Enrollment for its HST 001 Phase 1b/2a Trial for Androgenic Alopecia

Histogen a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, today announced the completion of patient enrollment ahead of schedule in its Phase 1b/2a clinical trial of HST 001, designed to assess the safety, tolerability and indicators of efficacy of HST 001 for the treatment of androgenic alopecia in men.

“We are pleased to have accomplished this clinical milestone with HST 001 and we look forward to completing the treatment phase of the study and releasing top-line data in the fourth quarter of this year,” said Richard W. Pascoe, Histogen’s President and CEO. “The on-time achievement of this milestone demonstrates our ability to execute on the clinical development plans for HST 001, which has the potential to stimulate new long-lasting hair growth in contrast to existing therapies that focus on reducing hair loss.”

About the HST 001 Phase 1a/2b Trial
This blinded, randomized, placebo-controlled, single-site study has enrolled 36 subjects with male pattern hair loss using a 2:1 randomization of HST 001 to placebo.

It is designed to assess the safety and tolerability of HST 001, as well as indicators of efficacy including non-vellus hair count, total hair count, and hair thickness density as measured by Canfield macrophotography.

At each treatment time point (Weeks 0, 6, and 12), subjects will receive a total of 20 injections divided between the temporal recession and vertex scalp areas, the most common regions of hair loss in men with androgenic alopecia.

Primary endpoints will be assessed at Week 18 and secondary endpoints at both Week 18 and Week 26. Top-line data is anticipated to be available in the fourth quarter of 2020.

About HST 001

HST 001, or Hair Stimulating Complex (HSC), is intended to be a physician-administered therapeutic for hair loss. We expect HSC to be a relatively safe, minimally invasive treatment that promotes new hair growth where existing treatments only reduce hair loss.

HSC is designed to enrich for growth factors including KGF, VEGF and follistatin, which are involved in signalling stem cells in the body and have been shown to be important in hair formation and the stimulation of resting hair follicles.

About Histogen

Histogen is a regenerative medicine company developing patented technologies that replace and regenerates tissues in the body. The company’s innovative technology platform utilizes cell-conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells, developing therapeutic products that address underserved, multi-billion US dollar global markets.

For more information, please visit www.histogen.com.

Histogen Announces Completion of Patient Enrollment for its HST 001 Phase 1b/2a Trial for Androgenic Alopecia in MenTop Line Results Expected Q4’2020

Source

Recent Posts

Alopecia Treatment Market

Alopecia Market

/in /by

Alopecia Market

The Alopecia Market is expected to reach USD 12.99 Billion by 2026, according to a new report by Reports and Data. This can be mainly associated with the rising predominance of chronic disorders such as hyperthyroidism, hypothyroidism, acute stress disorder, lupus, and hypopituitarism.

Moreover, increasing incidence of Hodgkin’s disease, Hashimoto’s disease, Addison’s disease, and celiac disease along with factors such as access to treatment quickly are expected to drive the market growth. However, the high cost of treatment and adverse side effects is expected to restrain the growth.

Also, changing lifestyle such as consumption of tobacco, an increase in the use of alcohol, and other associated products, growing stress levels, and the expanding population are expected to spur the market. Increasing disposable incomes coupled with expanding emphasis on aesthetic appearance are also likely to add to the demand for alopecia treatment worldwide.

Hair loss, also acknowledged as alopecia or baldness refers to a loss of hair from part of the head.

The typical pattern of hair loss can vary from a small area to the entire body. Scarring or inflammation is not present. Hair loss in some people may cause psychological distress. General types include female-pattern hair loss, male-pattern hair loss, alopecia areata, and a thinning of hair also known as telogen effluvium.

The cause of male-pattern hair loss is a combination of male hormones and genetics, the purpose of female pattern hair loss is not clear, the use of alopecia areata is auto-immune, and the cause of telogen effluvium is mostly a psychological or physically stressful event.

The rising number of the introduction of new drugs, consumer disposable incomes, and the complementary initiatives taken by the relevant organizations namely, AHLA and NAAF, are the crucial factors for the North America region to account for the largest market share of 22.30% in 2018.

Key Coverage of the Report

•Region and country-wise statistics of Alopecia Market from the period 2016-2026. While 2016-2017 has been utilized as historical data, 2018 is considered the base year. 2019-2026 have been derived as forecasts.
•Estimation of the market size along with historic and forecasted trend analysis.
•Various Cure Types of Alopecia Market technique have been analyzed. Statistical analysis has been conducted on obtaining the individual share of these segments.
•Regional up-coming Alopecia Market outlook.
•Regional prevalence of the market has been mapped.
•Demand and Supply GAP Analysis
•Regional Competitors Pricing Strategy
•Market share analysis of the top industry players
•Strategic recommendations for the new entrants
•Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
•Strategic recommendations in key business segments based on the market estimations
•Competitive landscaping mapping the key common trends
•Company profiling with detailed strategies, financials, and recent developments.

Salient Trends of the Alopecia Market

•The market is projected to grow at a CAGR of 1% in terms of value and reach USD 12.99 billion in 2026.
•Based on disease type, the alopecia market is classified into androgenetic alopecia, alopecia areata (AA), and others. Androgenetic type led this market in 2018 with the largest revenue of USD 3.65 billion in 2018 and is expected to grow at a favourable rate over the forecast period.
•Alopecia areata is an autoimmune skin disease identified by the hair loss on the scalp, face, and other areas of the body. Alopecia areata is segmented into totalis, patchy, and universalis further.
•The rising predominance of alopecia areata owing to autoimmune diseases such as diabetes, hyperthyroidism, and Down’s syndrome is expected to drive demand over the forecast period.
•Increasing predominance coupled with rising awareness regarding aesthetic appeal and physical appearance is also assumed to drive market growth in the next few years.
•Alopecia areata is expected to be the fastest-growing market with a CAGR of 5.2% during the forecast period.
•Steroid injections may treat alopecia areata in the affected area, but these need to be continuously repeated to be effective. Hair loss is a common problem. The pattern of hair loss by age 50 affects about half of males and a quarter of females. About 1-2% of people develop alopecia areata at some point in time.
•Male-Pattern Hair Loss (MPHL) or Androgenetic alopecia is associated with various medical conditions such as diabetes, coronary heart disease, obesity, prostate cancer, hypertension, and Polycystic Ovary Syndrome (PCOS).
•Also, the availability of treatments such as oral treatments, licensed topical treatments involving the use of finasteride and minoxidil; and surgical procedures such as hair replacement and transplantation are expected to drive the market.
•Laser treatments are also becoming common for non-invasive approach. Such non-invasive treatment approaches are also likely to drive the androgenetic segment.
•The global Alopecia Market is growing at a rapid speed owing to the increase in stress and changed lifestyle.
•The market can be classified into home care settings and dermatology clinics, based on application. Dermatology clinics account for the largest market share of 54.24% in 2018 and are anticipated to grow at a fruitful rate over the forecast period.
•Dermatology clinics coupled with innovative technologies and prescription hair care products help many affected individuals fight their condition.
•Consultation with dermatologists is regarded as the best option for the treatment, as they prescribe suitable medication or therapy for effective results. These factors are responsible for the high need for dermatology clinics for hair loss treatment.
•On the other hand, treatment in-home care settings is expected to grow at a rate of 5.1% during the forecast period.
•Prescription medicine segment is anticipated to grow owing to increasing disposable income and quickly changing lifestyle. Finasteride and Corticosteroids are some of the majorly prescribed medications.
•Based on the sales distribution, the market is segmented into prescription-based medications or treatment devices and Over the Counter (OTC).
•Sale of prescription products account for the larger market share of 68.85% in 2018 and is estimated to reach USD 5.95 billion by 2026.
•The OTC segment is expected to grow at a rate of 5.1% during the forecast period.
•Increasing R&D efforts to improve treatments, FDA approvals obtained for certain products and strategic initiatives taken by the key players, are the primary competitive strategies paving the way for market expansion.
•In April 2016, Johnson & Johnson announced the launch of a new global healthcare initiative to implement healthcare solutions, in Africa.
•The developing prosperity of countries such as Indonesia, Taiwan, China, and India is inviting new international ventures in these countries thereby leading to the growth of various industries in the APAC region.

Companies considered and profiled in this market study

Cipla Inc., Johnson and Johnson AG, Transitions Hair Pty Ltd., Sun Pharmaceutical Industries Ltd., Merck & Co., Inc.,  Cirrus Hair Centers, Lexington International LLC,  Vita-Cos-Med Klett-Loch GmbH, Follica, Inc., and Capillus.

Market-O-Nomics

•Rising demand for low-cost treatment, growing awareness regarding adverse effects of prescribed drugs, and the increasing availability of options are spurring the need for OTC products.
•Moreover, a surge in the number of FDA-approved OTC products for hair loss treatments is additionally expanding their demand. Some of the FDA-approved OTC products for hair loss treatment are Oscar Blandi hair lift instant thickening and strengthening serum and Keranique hair regrowth system.
•In 2018, the dominant gender segment for the alopecia market is women that accounts for the larger market share of 56.48%. The growing awareness amongst women about alopecia and the importance laid upon appearance by them are the key drivers of this segment.
•Due to the predominance of a vast number of new entrants established manufacturers, and suppliers in the market, the industry is extremely competitive.
•Asia Pacific is forecasted to witness the fastest CAGR of 5.4% during the forecast period. A vast population suffering from alopecia and growing awareness about the available therapeutic options are the key growth drivers.
•Economic development coupled with continually increasing per capita healthcare investment in emerging countries such as India, China, and Singapore is expected to create high growth opportunities.
•Innovations and technological trends in treatment, evolving healthcare expenditures, and increased healthcare facilities are expected to drive the growth further.

Segments Covered in the report:

This report forecasts revenue growth at a global, regional & country level, and provides an analysis on the industry trends in each of the sub-segments from 2018 to 2026.

For the purpose of this study, Reports and Data have segmented the global Alopecia Market on the basis of Disease, Gender, application, Sales distribution and region:

Disease Outlook (Revenue, USD Million; 2016-2026)

•Alopecia Areata
•Androgenetic Alopecia
•Others

Sales distribution Outlook (Revenue, USD Million; 2016-2026)

•Prescriptions
•OTC

Application Outlook (Revenue, USD Million; 2016-2026)

•Homecare Settings
•Dermatology Clinics

Gender Outlook (Revenue, USD Million; 2016-2026)

•Female
•Male

Regional Outlook (Revenue, USD Million; 2016-2026)

•North America

◦U.S.

•Europe

◦Germany
◦UK

•Asia Pacific

◦China
◦India
◦Southeast Asia

•Latin America

◦Brazil

•Middle East & Africa

Alopecia Market

Source

Recent Posts

One of a kind hair loss subscription box

One of a kind hair loss subscription box

/in /by

Helper Hair Box launches a unique one of a kind, hair loss subscription box

Toronto based company hopes to get their project out to the world with their hair loss subscription box for women and children.  Meant for those dealing with any form of hair loss; alopecia, cancer, thinning hair and trichotillomania (hair-pulling).

Founded by Heather Scott, she is the owner of Pretty Wigs To You, an online wig boutique specializing in wigs for women with alopecia and those undergoing cancer treatments.

Woman on Mission To Help Normalize Hair Loss. Heather Scott, Founder of the Toronto based Helper Hair Box, a subscription box for women and children with hair loss.

Heather has had alopecia since the age of 3 and is giving back to children with hair loss, she is donating a portion of boxes to children with hair loss and also donating wigs to children who need them. Helper Hair Box is currently on Kickstarter www.helperhairbox.com (CNW Group/Helper Hair Box)

These boxes were created to help encourage confidence in women and children going through hair loss. Each box is custom to the recipient and is filled with inspirational books, headbands, hats, makeup, confidence-building messages, and items to remind them that they are beautiful with or without hair.

There is currently nothing on the market exclusively dedicated to those with hair loss, as devastating as it can be to lose your hair, these boxes promote confidence and body positivity while getting the chance to try new products.

Their mission is to give back to children with hair loss, they will be donating a Helper Hair Box to a child for every 6 boxes sold and donating a wig to a child for every 12 boxes sold. Any funding that they receive on their Kickstarter campaign for these boxes will go directly towards purchasing the wigs, products, printing, and worldwide shipping costs.

Having suffered from alopecia herself since the age of 3, the founder and creator of these boxes have made it her life’s mission to help others. She personally knows how expensive wigs can be to purchase, which is why she has decided to give back to the hair loss community.

Heather lives just North of Toronto with her husband and three young children, she is an Amazon #1 best-selling author, owner of Pretty Wigs To You and inspiration and advocate for children with hair loss.

You can hear Heather’s story, see the Helper Hair Boxes for yourself, and help back this project currently on Kickstarter!

www.helperhairbox.com

Helper Hair Box launches a unique one of a kind, hair loss subscription box

Source

Recent Posts

Positive CTP-543 Results from Phase 2 Alopecia Areata Trial

CTP-543 for the Treatment of Alopecia Areata

/in /by

Concert Pharmaceuticals Receives FDA Breakthrough Therapy Designation for CTP-543 for the Treatment of Alopecia Areata

Concert Pharmaceuticals, Inc today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for the Company’s oral Janus kinase inhibitor, CTP-543, for the treatment of adult patients with moderate-to-severe alopecia areata.

There are currently no drugs approved by the FDA for the treatment of alopecia areata, an autoimmune disorder in which the immune system attacks hair follicles, resulting in patchy or complete hair loss.

FDA Breakthrough Therapy Designation is intended to expedite the development and review of medicines aimed at treating a serious or life-threatening disease where there is preliminary clinical evidence that the investigational therapy may offer a substantial improvement over existing therapies.

“We are pleased that the FDA has recognized the therapeutic potential of CTP-543 as a new treatment in development for alopecia areata,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “Our goal is to bring this potential new therapy to patients as quickly as possible. We look forward to working closely with the FDA to expedite the development of CTP-543.”

FDA Breakthrough Therapy Designation for CTP-543 is supported by positive data from a Phase 2 clinical trial in patients with moderate-to-severe alopecia areata.

In September 2019, Concert reported that patients treated with either 8 mg twice-daily or 12 mg twice-daily of CTP-543 met the primary efficacy endpoint with statistically significant differences (p <0.001) relative to placebo in the percentage of patients achieving a ≥ 50% relative change from baseline at 24 weeks as measured by Severity of Alopecia Tool (SALT).

The 8 mg twice daily and 12 mg twice-daily groups were also significantly different from placebo in the number of patients achieving a SALT score of 20 or less at 24 weeks, which is the primary efficacy endpoint that Concert intends to utilize in its pivotal registration studies. Treatment with CTP-543 was generally well-tolerated, with one serious adverse event reported in the 12 mg dose group where the patient was able to complete the trial after a brief dose interruption.

As the next step in the CTP-543 clinical program, Concert intends to initiate its Phase 3 clinical program in the fourth quarter of 2020.

CTP-543 has also received Fast Track designation in the U.S. for the treatment of alopecia areata.

Additional information about the CTP-543 Phase 2 results is available in the Scientific Presentations section of the Company’s website.

About the Phase 2 Trial Design of CTP-543 in Alopecia Areata

The Phase 2 trial was a double-blind, randomized, placebo-controlled, sequential dose trial to evaluate the safety and efficacy of CTP-543 in adult patients with moderate-to-severe alopecia areata.

A total of 149 patients were randomized to receive one of three doses of CTP-543 (4 mg, 8 mg or 12 mg) or placebo, administered twice-daily. The primary outcome measure utilized the SALT score after 24 weeks of dosing. The average baseline SALT score across all patients was approximately 88%, where 0% is no scalp hair loss and 100% represents total scalp hair loss.

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted Fast Track designation for CTP-543 for the treatment of alopecia areata. The Company intends to advance CTP-543 into Phase 3 evaluation in the fourth quarter of 2020.

c Alopecia areata may affect approximately 700,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. The onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017.

The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development. Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report.

Concert Pharmaceuticals Receives FDA Breakthrough Therapy Designation for CTP-543 for the Treatment of Alopecia Areata

Source

Recent Posts

Androgenic Alopecia Therapeutics Market

Androgenic Alopecia Therapeutics Market

/in /by

COVID-19 Impact on Global Androgenic Alopecia Therapeutics Market Size, Status and Forecast 2020-2026

This report focuses on the global Androgenic Alopecia Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Androgenic Alopecia Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

Johnson & Johnson
Merck
GlaxoSmithKline
Astellas Pharma
Cipla
Almirall
Sun Pharma
Reddy’s Laboratories
Concert Pharmaceuticals
RiverTown Therapeutics
Brickell Biotech
BiologicsMD
Aclaris Therapeutics

Market segment by Type, the product can be split into

Medicine
Surgery
Other

Market segment by Application, split into

Hospital
Clinic
Other

Market segment by Regions/Countries, this report covers

North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:

To analyze global Androgenic Alopecia Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Androgenic Alopecia Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Androgenic Alopecia Therapeutics are as follows:

History Year: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

COVID-19 Impact on Global Androgenic Alopecia Therapeutics Market Size, Status and Forecast 2020-2026

Source

Recent Posts

Global Alopecia Treatment

Global Alopecia Treatment

/in /by

Global Alopecia Treatment

Global Alopecia Treatment (Hair Loss) Market is expected to rise from its initial estimated value of USD 8.21 billion in 2018 to an estimated value of USD 12.40 billion by 2026 registering a CAGR of 5.3% in the forecast period of 2019-2026.

This rise in the market can be attributed to the rising geriatric population along with high demand for surgical hair transplant and changing lifestyle.

This Alopecia Treatment (Hair Loss) market analysis report profiles leading companies of the market along with the emerging new ventures who are creating an impact on the global market with their latest innovations and technologies.

The study includes information on key segmentation of the global Alopecia Treatment (Hair Loss)  market on the basis of type/product, application and geography (country/region).

Each of the segments included in the report is studied in relation to different factors such as market size, market share, value, growth rate and other quantitative information.

The competitive analysis included in this Alopecia Treatment (Hair Loss) market study allows readers to understand the difference between players and how they are operating among themselves on a global scale.

Few of the major market competitors currently working in the alopecia treatment (hair loss) market are

Cipla,

Viviscal,

Dr Reddy’s Laboratories Ltd.,

Regaine,

Merck & Co., Inc,

Ranbaxy Laboratories Ltd,

Phyto – Alès Groupe,

Kirkland Signature,

Vitabiotics,

Nanogen,

Key Developments in the Market:

In January 2018, Concert Pharmaceuticals, Inc. announced U.S. FDA granted Fast Track designation for CTP-543, a novel, oral Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe alopecia areata, a disease which attacks the hair follicles, leading to hair loss.

In May 2018, Histogen, Inc (U.S.) announced that received approval to Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) to study its lead product in female diffuse hair loss.

In March 2017, Perrigo Perrigo Company PLC (U.S.) announced the launch of over-the-counter Women’s Rogaine, which helps to regrow hair on top of the scalp.

Table Of Content:

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Global Alopecia Treatment (Hair Loss) Market Landscape

Part 04: Global Alopecia Treatment (Hair Loss) Market Sizing

Part 05: Global Alopecia Treatment (Hair Loss) Market Segmentation By Product

Part 06: Five Forces Analysis

Part 07: Customer Landscape

Part 08: Geographic Landscape

Part 09: Decision Framework
Part 10: Drivers And Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Vendor Analysis

Global Alopecia Treatment

Source

Recent Posts

Alopecia Treatment Market

Alopecia Treatment Market

/in /by

Global Alopecia Treatment Market Size Share Forecast 2025

Alopecia also called as hair loss or baldness is a very common condition affecting people across the globe. Alopecia can affect people of all gender and at any stage of life, it generally it affects mid-aged generation. For instance, according the data published by Arch Argent Pediatr in 2017, the prevalence of Alopecia areata is high in the age group of 10 and 25 years and around 60% of people under these age group suffer from Alopecia areata.

Market Dynamics

Product launches, approvals, and a robust pipeline of novel products is expected to be the major driver of the growth of the global alopecia treatment market. For instance, in 2016, Cellmid Limited, a wholly-owned subsidiary, Advangen Limited launched new hair loss product évolis in U.S. market.

In May 2018, Histogen, Inc., received the approval of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to study its lead product Hair Stimulating Complex (HSC660) in female diffuse hair loss. HSC660 is an investigational injectable treatment for alopecia and is expected to get FDA approval in the near future. Key players in the market are engaged in strategic collaborations for increasing geographic presence in the market.

For instance, in May 2018, Cellmid Limited signed a collaborative agreement with Beijing Fukangren Bio-pharm Tech Co Ltd. for distribution of its product in the Peoples Republic of China. Furthermore, the increasing prevalence of alopecia worldwide is expected to drive the growth of the market.

According to the data published by National Center for Biotechnology Information (NCBI), in 2015, androgenetic alopecia is a most prevalent autoimmune disorder and the second most prevalent hair loss disorder and around 2% population worldwide is suffering from androgenetic alopecia.

Key features of the study:

• This report provides in-depth analysis of alopecia treatment market and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year

• It elucidates potential revenue opportunity across different segments and explains the attractive investment proposition matrix for this market

• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players

• It profiles leading players in the global alopecia treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans

• Key companies covered as a part of this study include Histogen, Inc., Aclaris Therapeutics, Inc., Concert Pharmaceuticals, Inc., HCell Inc., GlaxoSmithKline plc., Daiichi Sankyo, Inc., Cipla Limited, and others.

• Insights from this report would allow marketers and the management authorities of the companies to make an informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics

• The global alopecia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

• Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the alopecia treatment market

Detailed Segmentation:

• Global Alopecia Treatment Market, By Disease Type :

o Androgenic Alopecia
o Alopecia Areata
o Ciatricial Alopecia
o Traction Alopecia
o Alopecia Totalis

• Global Alopecia Treatment Market, By Drug Type:

o Vasodilators
o Minoxidil
o 5-Alpha Reductase Inhibitors
o Finasteride
o Corticosteroids
o Immunosuppressants
o Cyclosporine
o Others
o Others

• Global Alopecia Treatment Market, By Gender:

o Male
o Female

• Global Alopecia Treatment Market, By Route of Administration:

o Oral
o Topical
o Injectable

• Global Alopecia treatment market, By Distribution Channel:

o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies

• Global Alopecia treatment market, By Geography:

Global Alopecia Treatment Market Size Share Forecast 2025

Source

Recent Posts

hair loss and stem cells

Platelet Rich Plasma and Stem Cell Alopecia Treatment

/in /by

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size And Forecast

The Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2020 to 2027.

The Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market report provide a holistic evaluation of the market for the forecast period (2018–2027). The report comprises of various segments as well an analysis of the trends and factors that are playing a substantial role in the market.

These factors; the market dynamics, involves the drivers, restraints, opportunities and challenges through which the impact of these factors in the market are outlined. The drivers and restraints are intrinsic factors whereas opportunities and challenges are extrinsic factors of the market. The Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market study provide an outlook on the development of the market in terms of revenue throughout the prognosis period.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: Scope of the Report

This report provides an all-inclusive environment of the analysis for the Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market. The market estimates provided in the report are the result of in-depth secondary research, primary interviews and in-house expert reviews. These market estimates have been considered by studying the impact of various social, political and economic factors along with the current market dynamics affecting the Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market growth

Along with the market overview, which comprises of the market dynamics the chapter includes Porter’s Five Forces analysis which explains the five forces: namely buyers bargaining power, suppliers bargaining power, the threat of new entrants, threat of substitutes, and degree of competition in the Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market.

It explains the various participants, such as system integrators, intermediaries and end-users within the ecosystem of the market. The report also focuses on the competitive landscape of the Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: Competitive Landscape

The market analysis entails a section solely dedicated for major players in the Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market wherein our analysts provide an insight to the financial statements of all the major players along with its key developments product benchmarking and SWOT analysis. The company profile section also includes a business overview and financial information. The companies that are provided in this section can be customized according to the client’s requirements.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market, By Product

• Androgenic Alopecia
• Congenital Alopecia
• Cicatricial Or Scarring Alopecia

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market, By Application

• Hospital
• Dermatology Clinic
• Other

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market, By Geography

• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Rest of Asia Pacific
• Rest of the World
o Latin America
o Middle East & Africa

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market, Key Players

• Kerastem
• Eclipse
• Stemcell Technologies
• RepliCel Life Sciences
• Regen Lab SA
• Histogen
• Glofinn Oy.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: Research Methodology

The research methodology is a combination of primary research secondary research and expert panel reviews. Secondary research includes sources such as press releases company annual reports and research papers related to the industry. Other sources include industry magazines, trade journals, government websites and associations were can also be reviewed for gathering precise data on opportunities for business expansions in Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market.

Primary research involves telephonic interviews various industry experts on acceptance of appointment for conducting telephonic interviews sending questionnaire through emails (e-mail interactions) and in some cases face-to-face interactions for a more detailed and unbiased review on the Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market, across various geographies.

Primary interviews are usually carried out on an ongoing basis with industry experts in order to get recent understandings of the market and authenticate the existing analysis of the data. Primary interviews offer information on important factors such as market trends market size, competitive landscape growth trends, outlook etc.

These factors help to authenticate as well as reinforce the secondary research findings and also help to develop the analysis team’s understanding of the market.

Reasons to Purchase this Report:

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size And Forecast

Source

Previous Posts

CTP-543 Phase 3 Trials in Alopecia Areata

Clinical Trial of CTP-543Clinical Trial of CTP-543

/in /by

Concert Pharmaceuticals Releases Additional Data from Phase 2 Clinical Trial of CTP-543 in Alopecia Areata

Concert Pharmaceuticals, Inc. today released new data analyses from its Phase 2 dose-ranging clinical trial of its investigational agent CTP‑543 for the treatment of moderate-to-severe alopecia areata.

The results were selected as an oral presentation at the Late-Breaking Research Program at the American Academy of Dermatology (AAD) Annual Meeting; however, the in-person meeting, originally scheduled for March 21, 2020, in Denver, was converted to a virtual meeting. The corresponding abstract was published by AAD in connection with the virtual meeting.

The data analyses released by Concert build on the previously-reported Phase 2 primary efficacy analysis which showed that administration of 8 mg twice daily and 12 mg twice-daily doses of CTP-543 for 24 weeks produced a statistically significantly greater number of responders compared to placebo.

A responder was defined as a ≥ 50% relative reduction in the Severity of Alopecia Tool (SALT) score at Week 24 compared to baseline. In the new analyses, statistically significant results were reported for the 8 mg and 12 mg twice-daily doses at more stringent response thresholds, which may be more clinically meaningful to patients, and positive findings were reported for clinician and patient-reported outcome measures of scalp hair loss.

“We believe that these data from our Phase 2 dose-ranging study set a new benchmark for clinical efficacy in treating alopecia areata and provide important information to inform our planned Phase 3 trials with CTP-543.

Since both the 8 mg and 12 mg twice-daily doses resulted in statistically significant improvement in SALT scores compared to placebo and exhibited a generally well-tolerated safety profile, we plan to assess both doses in our Phase 3 program,” said James V. Cassella, Ph.D., Chief Development Officer of Concert Pharmaceuticals. “Importantly, we would like to thank the alopecia areata patients for their participation in this study, as well as the clinical investigators and research staff for their significant efforts to support the development of CTP-543.”

Key new findings further highlight the positive efficacy results in the Phase 2 study, including:

  • Meaningful hair regrowth: At Week 24, 26% and 42% of patients who received CTP-543 in the 8 and 12 mg twice-daily cohorts, respectively, achieved an absolute SALT score ≤ 20 (p <0.05 vs. placebo), indicating a clinically-meaningful 80 per cent or greater scalp hair present. In addition, 36% of patients in the 12 mg twice-daily cohort achieved an absolute SALT score ≤ 10 (p <0.05 vs. placebo) at Week 24.
  • Clinical Global Impression of Improvement: Data from the Clinician Global Impression of Improvement scale showed 75% of clinicians rated the response in the 12 mg twice-daily cohort and 61% of clinicians rated the response in the 8 mg twice-daily cohort as “much improved” or “very much improved” at Week 24. For both doses, there was a statistically significant difference from placebo (p <0.001).
    • Similarly, previously-reported data from the Phase 2 trial for the Patient Global Impression of Improvement scale showed 78% of patients receiving 12 mg twice daily and 58% of patients receiving 8 mg twice-daily rated their alopecia areata as “much improved” or “very much improved” at Week 24. For both doses, there was a statistically significant difference from placebo (p <0.001).

In Phase 2 dose-ranging trial, the most common (≥10%) side effects in the 8 mg or 12 mg CTP-543 dose groups were headache, nasopharyngitis, upper respiratory tract infection, acne, nausea and low-density lipoprotein increase. One serious adverse event of facial cellulitis was reported in the 12 mg dose group as possibly related to treatment. After a brief dosing interruption, treatment was continued, and this patient completed the trial. No thromboembolic events were reported during the trial.

Slides summarizing the new analyses are available in the Scientific Presentations section of Concert’s website.

About the Phase 2 Trial Design of CTP-543 in Alopecia Areata

The Phase 2 trial was a double-blind, randomized, placebo-controlled, sequential dose trial to evaluate the safety and efficacy of CTP-543 in adult patients with moderate-to-severe alopecia areata. A total of 149 patients were randomized to receive one of three doses of CTP-543 (4 mg, 8 mg or 12 mg) or placebo, administered twice-daily. The primary outcome measure utilized the SALT score after 24 weeks of dosing. The average baseline SALT score across all patients was approximately 88%, where 0% is no scalp hair loss and 100% represents total scalp hair loss. All patients who completed 24 weeks of treatment in the 12 mg dosing cohort had the opportunity to continue in a separate extension study to evaluate long-term safety and efficacy of CTP-543.

Previously-reported data from the Phase 2 trial demonstrated a relative reduction in overall SALT scores from baseline at Week 24, the primary efficacy endpoint of the study. In the 12 mg twice-daily cohort, 58% of patients achieving a ≥ 50% relative reduction in their overall SALT score from baseline compared to 9% for placebo (p <0.001). In the 8 mg twice-daily cohort, 47% of patients achieved the primary endpoint compared to placebo (p <0.001).

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted Fast Track designation for CTP-543 for the treatment of alopecia areata. The Company intends to advance CTP-543 into Phase 3 evaluation in the fourth quarter of 2020.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect approximately 700,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. The onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017.

The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development. Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report. Additional information on the PFDDI is available online.

Concert Pharmaceuticals Releases Additional Data from Phase 2 Clinical Trial of CTP-543 in Alopecia Areata

1 Benigno M. Clinical, Cosmetic and Investigational Dermatology. 2020.

 

Previous Posts